Status:
COMPLETED
Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
Lead Sponsor:
Warner Chilcott
Collaborating Sponsors:
Sanofi
Conditions:
Other Osteoporosis
Eligibility:
MALE
30+ years
Phase:
PHASE3
Brief Summary
Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study.
Eligibility Criteria
Inclusion
- Documented osteoporosis of the femoral neck and lumbar spine
Exclusion
- BMI greater than or equal to 35
Key Trial Info
Start Date :
June 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
285 Patients enrolled
Trial Details
Trial ID
NCT00619957
Start Date
June 1 2002
End Date
May 1 2007
Last Update
October 28 2011
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Palm Desert, California, United States, 92260
2
Research Site
Lakewood, Colorado, United States, 80227
3
Research Site
Stuart, Florida, United States, 34996
4
Research Site
St Louis, Missouri, United States, 63110